© 2020 MJH Life Sciences and Urology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Urology Times. All rights reserved.
November 30, 2020
The findings support continued investigation of the safety and efficacy of mirabegron in men with OAB and concurrent ED, says study author Arthur L. Burnett, II, MD, MBA.
November 23, 2020
Men using the RestoreX traction device saw a median 1.6-cm increase in length at 6 months, versus a median of 0.3 to 0.7 cm for controls.
November 18, 2020
Christopher Warren discusses steps urologists can take to create and/or share patient education videos regarding Peyronie disease.
October 16, 2020
Men who receive care for erectile dysfunction from their primary care provider are much less likely to receive advanced pharmacological therapies for management of their condition than those treated by urologists.
September 04, 2020
Ranjith Ramasamy, MD, discusses a recent study evaluating the testosterone nasal gel Natesto.
September 01, 2020
"While we generally don’t perform surgery for PD in the first year, it makes sense to treat these patients earlier with intralesional collagenase clostridium histolyticum," says Wayne J.G. Hellstrom, MD.
July 22, 2020
Retreatment rates were low with both aquablation and transurethral resection of the prostate.
July 21, 2020
In patients with prior exposure to PDE5 inhibitors, increasing the number of sessions of low-intensity shockwave therapy was associated with improving outcomes.
July 17, 2020
Trinity Bivalacqua, MD, PhD, discusses the available evidence for the use of restorative therapies for erectile dysfunction.
July 20, 2018
The AUA 2018 sexual dysfunction take-home messages also included a novel end-to-side nerve grafting procedure for men with post-radical-prostatectomy ED as well as the finding that use of a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor does not appear to change the adverse effect profile of flibanserin (Addyi).